Redx Pharma Management

Management criteria checks 3/4

Redx Pharma's CEO is Lisa Mary Anson, appointed in Jun 2018, has a tenure of 5.92 years. total yearly compensation is £608.13K, comprised of 94.9% salary and 5.1% bonuses, including company stock and options. directly owns 0.19% of the company’s shares, worth €125.53K. The average tenure of the management team and the board of directors is 3 years and 3 years respectively.

Key information

Lisa Mary Anson

Chief executive officer

UK£608.1k

Total compensation

CEO salary percentage94.9%
CEO tenure5.9yrs
CEO ownership0.2%
Management average tenure3yrs
Board average tenure3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Lisa Mary Anson's remuneration changed compared to Redx Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2023UK£608kUK£577k

-UK£33m

Jun 30 2023n/an/a

-UK£31m

Mar 31 2023n/an/a

-UK£29m

Dec 31 2022n/an/a

-UK£24m

Sep 30 2022UK£637kUK£606k

-UK£18m

Jun 30 2022n/an/a

-UK£18m

Mar 31 2022n/an/a

-UK£19m

Dec 31 2021n/an/a

-UK£20m

Sep 30 2021UK£2mUK£615k

-UK£22m

Jun 30 2021n/an/a

-UK£20m

Mar 31 2021n/an/a

-UK£18m

Dec 31 2020n/an/a

-UK£14m

Sep 30 2020UK£619kUK£481k

-UK£9m

Jun 30 2020n/an/a

-UK£8m

Mar 31 2020n/an/a

-UK£6m

Dec 31 2019n/an/a

-UK£5m

Sep 30 2019UK£439kUK£390k

-UK£4m

Jun 30 2019n/an/a

-UK£5m

Mar 31 2019n/an/a

-UK£7m

Dec 31 2018n/an/a

-UK£8m

Sep 30 2018UK£372kUK£100k

-UK£9m

Compensation vs Market: Lisa Mary's total compensation ($USD771.26K) is above average for companies of similar size in the German market ($USD384.52K).

Compensation vs Earnings: Lisa Mary's compensation has been consistent with company performance over the past year.


CEO

Lisa Mary Anson (55 yo)

5.9yrs

Tenure

UK£608,127

Compensation

Mrs. Lisa Mary Whewell Anson serves as the Chief Executive Officer and Executive Director at Redx Pharma PLC since June 1, 2018. She has been President of AstraZeneca UK since 2012 and brings significant l...


Leadership Team

NamePositionTenureCompensationOwnership
Lisa Mary Anson
CEO & Executive Director5.9yrsUK£608.13k0.19%
€ 125.5k
Peter Collum
Chief Financial Officer3yrsno datano data
James Mead
Chief Operating Officer3yrsUK£210.91kno data
Richard Armer
Chief Scientific Officer10.3yrsno datano data
Karl Hard
Head of Investor Relationsno datano datano data
Claire Solk
General Counsel & Company Secretary2.3yrsno datano data
Caitlin Pearson
Head of Communications2.1yrsno datano data
Cliff Jones
Senior Vice President of Chemistry8.3yrsno datano data
Caroline Phillips
Senior Vice President of Biologyno datano datano data
Craig Tilston
Head of Development Operationsno datano datano data
Helen McKeever
Head of Nonclinical Development3.3yrsno datano data
Helen Timmis
Interim Chief Medical Officerless than a yearno datano data

3.0yrs

Average Tenure

55yo

Average Age

Experienced Management: 0RX's management team is considered experienced (3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Lisa Mary Anson
CEO & Executive Director5.9yrsUK£608.13k0.19%
€ 125.5k
Peter Presland
Independent Non-Executive Director6.5yrsUK£48.75k0.038%
€ 24.4k
Joseph Anderson
Non-Executive Directorless than a yearno datano data
Bernhard Kirschbaum
Independent Non-Executive Director8.3yrsUK£49.00kno data
Jane Griffiths
Independent Non-Executive Chair2.4yrsUK£85.00k0.022%
€ 14.2k
Robert Andrew Scott
Independent Non-Executive Director2.3yrsUK£41.50kno data
Natalie Berner
Shareholder Representative Non-Executive Director3yrsno datano data

3.0yrs

Average Tenure

65yo

Average Age

Experienced Board: 0RX's board of directors are considered experienced (3 years average tenure).